Allurion Technologies reported a transformative second quarter, highlighting strategic pivots towards innovative obesity care solutions and a strong performance in key growth accounts.
- Transitioned distribution strategy to focus on partners promoting comprehensive obesity management, resulting in a 20% growth in targeted accounts.
- Initiated development of a novel GLP-1 drug-eluting intragastric balloon, addressing adherence issues and enhancing treatment efficacy.
- Submitted the final module of the PMA application on schedule, demonstrating significant weight loss efficacy exceeding preset target margins.
- Resized sales force to prioritize high-performing accounts, positioning for long-term growth potential outside the U.S. market.
- Launched a multicenter study in Europe to validate combination therapy's impact on weight loss and GLP-1 adherence, with enrollment expected by year-end.
Community Discussion